NasdaqCM:PLSEMedical Equipment
Assessing Pulse Biosciences (PLSE) Valuation After Upcoming nPulse Cardiac Study Data Presentation
Why the latest nPulse study update matters for Pulse Biosciences (PLSE)
Pulse Biosciences (PLSE) just flagged a fresh catalyst, with late-breaking 6- and 12-month data from its first-in-human nPulse Cardiac Catheter Ablation System study set for presentation at the 31st Annual AF Symposium 2026.
See our latest analysis for Pulse Biosciences.
The upcoming AF Symposium data drop lands after a mixed year for investors, with a 9.93% year to date share price return to US$14.72, a 16.36% 3 month...